



# Development of tissue factor-targeted liposomes for effective drug delivery to stroma-rich tumors

メタデータ	言語: English
	出版者: Elsevier
	公開日: 2021-10-05
	キーワード (Ja):
	キーワード (En): Antibody, liposome, pancreatic tumor,
	targeting, tissue factor, tumor stroma
	作成者: Shimizu, Kosuke, Takeuchi, Yoshihito, Otsuka,
	Kazuma, Mori, Tomoya, Narita, Yudai, Takasugi, Shohei,
	Magata, Yasuhiro, Matsumura, Yasuhiro, Oku, Naoto
	メールアドレス:
	所属:
URL	http://hdl.handle.net/10271/00003896
	This work is licensed under a Creative Commons

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 International License.



1	Development of tissue factor-targeted liposomes for effective drug delivery to stroma-rich
2	tumors
3	
4	Kosuke Shimizu <sup>a,b,*</sup> , Yoshihito Takeuchi <sup>b</sup> , Kazuma Otsuka <sup>b</sup> , Tomoya Mori <sup>b</sup> , Yudai Narita <sup>a,b</sup> ,
5	Shohei Takasugi <sup>b</sup> , Yasuhiro Magata <sup>a</sup> , Yasuhiro Matsumura <sup>c</sup> , Naoto Oku <sup>b,d,**</sup>
6	
7	<sup>a</sup> Department of Molecular Imaging, Institute of Medical Photonics Research, Preeminent Medical
8	Photonics Education & Research Center, Hamamatsu University School of Medicine, 1-20-1
9	Handayama, Higashi-ku, Hamamatsu City, Shizuoka 431-3192, Japan
10	<sup>b</sup> Department of Medical Biochemistry, School of Pharmaceutical Sciences, University of
11	Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka City, Shizuoka 422-8526, Japan
12	°Division of Developmental Therapeutics, Exploratory Oncology Research & Clinical Trial
13	Center, National Cancer Center, 6-5-1 Kashiwanoha, Kashiwa City, Chiba 277-8577, Japan
14	<sup>d</sup> Laboratory of Bioanalytical Chemistry, Faculty of Pharma-Science, Teikyo University, 2-11-1
15	Kaga, Itabashi-ku, Tokyo 173-8605, Japan
16	
17	*Corresponding author:
18	Kosuke Shimizu, Ph.D.
19	Department of Molecular Imaging, Institute for Medical Photonics Research, Preeminent Medical
20	Photonics Education & Research Center, Hamamatsu University School of Medicine
21	1-20-1 Handayama, Higashi-ku, Hamamatsu City, Shizuoka 431-3192, Japan
22	kshimizu@hama-med.ac.jp
23	
24	** Corresponding author:
25	Naoto Oku, Ph.D.
26	Laboratory of Bioanalytical Chemistry, Faculty of Pharma-Science, Teikyo University
27	2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan
28	noku@pharm.teikyo-u.ac.jp
29	
30	Keywords: Antibody; liposome; pancreatic tumor; targeting; tissue factor; tumor stroma

### 31 Abstract

32 Tissue factor (TF), which is well known as a trigger molecule of extrinsic coagulation, is found 33 in not only tumor cells but also in stromal cells in tumor tissues. Thus, TF is a candidate molecule 34 to potentially enable targeting of both tumor cells and stromal cells for anti-cancer drug delivery. 35 Herein, we prepared liposomes conjugated with the Fab' fragment of anti-TF antibody (TF Ab-36 Lip) and evaluated the capability for drug delivery to stroma-rich tumors for realizing a whole 37 tumor tissue-targetable strategy. When the targetability of TF Ab-Lip to TF-expressing KLN205 38 squamous tumor cells and NIH3T3 fibroblast cells were examined, TF Ab-Lip was significantly 39 taken up into both cells compared with non-targeted liposomes. Corresponding to this result, 40 doxorubicin-encapsulated TF Ab-Lip (TF Ab-LipDOX) showed potent cytotoxicity against 41 KLN205 cells. In vivo experiments using KLN205 solid tumor-bearing mice indicated that TF Ab-Lip became highly accumulated and distributed widely in not only the tumor cell region but 42 43 also in the stromal one in the tumor. Treatment with TF Ab-LipDOX significantly suppressed the 44 growth of KLN205 solid tumors. Furthermore, TF Ab-Lip targetable both mouse and human TF 45 (mhTF Ab-Lip) became distributed throughout stroma-rich human pancreatic BxPC3 tumors and the treatment of the BxPC3 tumor-bearing mice with mhTF Ab-LipDOX showed highest tumor-46 47 suppressive effect. These data suggest that TF Ab-Lip could achieve effective accumulation for 48 stroma-rich tumor treatment.

### 49 **1. Introduction**

50 The importance of the tumor microenvironment in tumor malignancy is attracting 51 much attention, and the tumor stroma is one of the factors composing this microenvironment. 52 Theise et al. recently demonstrated that stroma functions not only in human body homeostasis 53 but also in tumor metastasis and advocated that the stroma is an "organ" in the body [1]. In fact, 54 stromal cells are widely distributed in certain malignant tumor tissues such as pancreatic tumors 55 and gliomas; and they promote tumor cell growth by making contact with each other and secreting 56 certain cytokines such as transforming growth factor (TGF)- $\beta$  [2, 3]. Furthermore, the tumor 57 stroma is involved in drug resistance by working just like a defense wall against the blood flow 58 components and circulating drugs and thus preventing drug penetration into the internal area of 59 tumor tissues [4]. Thus, the anti-tumor approach with emphasis on the tumor stroma is now being 60 considered [5].

61 On the other hand, since the relationship between tumor development and blood 62 coagulation has been advocated [6] and clinical data indicate that cancer patients frequently suffer 63 from thrombosis [7], the expression of blood-coagulation factors in tumor tissue is now a topic 64 for discussion [8, 9]. Among these factors, tissue factor (TF), also referred to as thromboplastin 65 or blood coagulation factor III, is a 47-kDa transmembrane glycoprotein that is known to work as 66 an initiator in extrinsic coagulation protease cascades: TF is expressed in the extravascular stroma 67 in normal tissues, where it can avoid contact with the blood circulation under physiological 68 conditions. However, when external physical damage to the tissues occurs, TF makes contact with 69 other blood coagulation factors such as factor VII, thus initiating the blood coagulation process. 70 Besides, enhanced expression of TF has also been found in various kinds of tumors; and the 71 expression is notably observed throughout the tumor tissue; i.e., TF is expressed in not only 72 angiogenic vessels and stromal cells but also in tumor cells in the tumor tissues [10, 11]. Therefore, 73 TF would seem to be a suitable target molecule for effective drug delivery to stroma-rich tumors.

74 The liposome is a highly safe and valuable drug nanocarrier and is used for effective 75 drug delivery to disease sites and improving the pharmaceutical problems of ingredients. In fact, 76 liposomal formulations encapsulating anti-cancer drugs have already been used for cancer 77 chemotherapy all over the world; and therapeutic advantages such as shrinkage of solid tumors 78 and reduced side effect have been obtained [12]. However, the application of liposomal agents 79 has been limited in some kinds of tumors; and insufficient therapeutic efficacy toward stroma-80 rich tumors such as pancreatic tumors has been noted. Therefore, to overcome the weak points of 81 liposomal drugs, a new liposome delivery approach avoiding the defense by tumor stroma must be proposed. Herein, to improve the therapeutic efficacy of liposomal drug toward stroma-rich tumors, we prepared liposomes conjugated with the Fab' fragment of anti-TF antibody, which

84

84 enabled targeting not only TF-expressing tumor cells but also TF-expressing stromal cells.

- 85 Using such liposomes, we evaluated the capability for whole tumor tissue-targeting delivery.
- 86

## 87 2. Materials and Methods

88 2.1. Materials

Anti-mouse TF rat monoclonal IgG<sub>2a</sub> antibody was produced and purified as previously reported, and clone 1157 was used in each experiment. Mouse recombinant tissue factor was purchased from R&D Systems. Distearolyphosphatidylcholine (DSPC), cholesterol (Cho), and *N*-(Carbonyl-methoxypolyethyleneglycol 2000)-1,2-distearoyl-*sn*-glycero-3-

93 phosphoethanolamine (DSPE-MPEG) were obtained from Nippon Fine Chemical Co., Ltd.

94 (Takasago, Hyogo, Japan). *N*-[(3-Maleimide-1-oxopropyl)aminopropyl polyethyleneglycol

95 2000-carbamyl] distearoylphosphatidyl-ethanolamine (SUNBRIGHT DSPE-020-MA, DSPE-

- 96 PEG-Mal) was purchased from NOF Corporation (Tokyo, Japan). 1,1'-Dioctadecyl-3,3,3',3'-
- 97 tetramethylindocarbocyanine perchlorate (DiIC<sub>18</sub>),

3,3'-dioctadecyloxacarbocyanine perchlorate (DiOC<sub>18</sub>), and 1,1'-dioctadecyltetramethyl
 indotricarbocyanine iodide (DiR) were procured from Life Technologies Japan (Tokyo, Japan).

100

101 *2.2. Cell culture* 

102 Mouse squamous tumor cell line KLN205, mouse melanoma cell line B16F10 (B16), 103 mouse colon carcinoma cell line Colon26 NL-17 (Colon26), mouse fibroblast cell line NIH3T3, 104 and mouse endothelial cell line 2H-11 were cultured in D-MEM (high glucose) medium (Wako 105 Pure Chemical Industries) supplemented with 10% heat-inactivated FBS (Hyclone, GE 106 Healthcare Japan), 100 µg/mL streptomycin (MP Biomedicals), and 100 units/mL penicillin (MP 107 Biomedicals) at 37°C in a humidified atmosphere with 5% CO<sub>2</sub>. Human pancreatic 108 adenocarcinoma cell line BxPC3 and human pancreatic cancer cell line Suit-2 were also cultured 109 in RPMI-1640 medium (Wako Pure Chemical Industries) containing 10% FBS.

110

111 *2.3. Animals* 

DBA/2 male mice and BALB/c nu/nu male mice were purchased from Japan SLC
(Shizuoka, Japan). All animal experiments were performed at the University of Shizuoka and
approved by the Animal and Ethics Committee of the University of Shizuoka. The animals were

115 cared for according to the Animal Facility Guidelines of the University of Shizuoka. For 116 preparation of solid tumor-bearing mice, KLN205 cells in D-MEM medium were subcutaneously 117 implanted ( $5 \times 10^6$  cells/0.2 mL/mouse) into DBA/2 male mice; and when the tumor size reached 118 about 1 cm in diameter, the tumor-bearing mice were used for each experiment. To prepare human 119 pancreatic tumor-bearing mice, we implanted BxPC3 cells ( $5 \times 10^6$  cells / 0.2 mL / mouse) 120 subcutaneously into BALB/c nu/nu male mice.

121

### 122 2.4. Western blotting

123 Cultured cells were lysed for 30 min at 4°C with 1% Triton X-100/Tris buffer (pH 7.4) 124 containing protease inhibitors (10 mM PMSF, 200 µg/mL Aprotinin, 200 µg/mL Pepstatin-A, and 125 200 µg/mL Leupeptin); and the amount of protein was determined by use of a BCA protein assay 126 kit (PIERCE). The protein samples were subjected to SDS-PAGE, transferred to a PVDF 127 membrane (Millipore), and blocked with 3% BSA in TTBS (0.9% NaCl, 0.1% Tween20, 20 mM 128 Tris-HCl; pH 7.4). The primary antibodies used were rat anti-mouse TF monoclonal antibody, rat 129 anti-human TF monoclonal antibody, and rabbit anti-β-actin polyclonal antibody (SIGMA-130 Aldrich). Goat anti-rat IgG horseradish peroxidase (HRP)-conjugated antibody or donkey antirabbit IgG HRP-conjugated antibody (Thermo Fisher Scientific) was used as the secondary 131 132 antibodies. The PVDF membrane was developed with ECL prime reagent (GE Healthcare) and 133 scanned with a LAS-3000UVmini (Fujifilm). Solid tumor samples were lysed with a tissue-134 protein extraction reagent (Thermo Fisher Scientific). and the expression of TF was determined 135 by Western blotting as described above.

136

# 137 2.5. Immunostaining

138 KLN205 solid tumors were harvested from the tumor-bearing mice, embedded in 139 optical cutting temperature (O.C.T.) compound, and frozen at -80°C with dry ice. Ten-micrometer 140 frozen sections were prepared with a HM505E cryostatic microtome (MICROM) and transferred 141 to MAS-coated glass slides (Matsunami Glass Ind., Ltd.). Then, the tumor sections were fixed 142 with 4% paraformaldehyde-PBS and thereafter blocked with 3% BSA-PBS at room temperature. 143 For TF staining, sections were probed with anti-mouse TF monoclonal rat antibody (clone 1157) 144 as the primary antibody followed by Alexa Fluor 488 anti-rat IgG antibody as the secondary 145 antibody (Thermo Fisher Scientific); and for  $\alpha$ -SMA staining, with Cy3-conjugated anti- $\alpha$ -SMA 146 antibody (SIGMA-Aldrich). In the case of EpCAM staining as a marker of tumor cells, sections 147 were incubated with anti-EpCAM rabbit antibody (Abcam) as the primary antibody followed by

Alexa Fluor 488 anti-rabbit IgG antibody (Thermo Fisher Scientific) as the secondary antibody.
After having been washed with PBS, the sections were incubated with DAPI for nuclear staining.
Finally, the sections were mounted with PermaFluor<sup>™</sup> Aqueous Mounting Medium (Thermo
Fisher Scientific). The fluorescence was observed by use of a confocal laser-scanning microscope
(LSM510META, Carl Zeiss).

153

# 154 2.6. Preparation of Fab' fragment of anti-TF monoclonal IgG antibody

155 Whole anti-mouse TF rat IgG<sub>2a</sub> monoclonal antibody in 100 mM sodium citrate buffer 156 (pH 3.5) was mixed with pepsin (4 w/w%; from porcine gastric mucosa, Sigma-Aldrich) and 157 incubated at 37°C for 3 h to eliminate the Fc region of the IgG antibody. After the reaction was 158 stopped by the addition of 3 M Tris HCl buffer (pH 8.0), the generated F(ab')<sub>2</sub> fragment was washed with 100 mM phosphate buffer (pH 6.8) and concentrated with an Amicon® Ultra-15 159 160 (30,000 NMWL, MILLIPORE). Then, the F(ab')<sub>2</sub> was reduced by reacting it with 2.5 mM 161 cysteamine hydrochloride (Wako) at 37°C for 90 min, after which the reaction solution was 162 purified by gel-filtration chromatography ( $\varphi$ 1 cm x 45 cm, Ultrogel AcA54, PALL Life Sciences) 163 to obtain the Fab' fragment. The Fab' fraction was determined by measuring the absorbance at 164 280 nm and concentrated by ultrafiltration with an Amicon® Ultra-4 (30,000 NMWL, 165 MILLIPORE).

166

### 167 2.7. Preparation of anti-TF antibody-conjugated liposomes

168 DSPC and cholesterol (2 : 1 as a molar ratio) were mixed in chloroform solution and 169 lyophilized with t-butanol. Then, the lipids were hydrated with HEPES-buffered solution (pH 7.4) 170 heated up to 60°C and subsequently frozen in liquid nitrogen and thawed repeatedly for 3 cycles. 171 After sonication for 10 min, the liposomes were passed through 100-nm pore-size polycarbonate 172 membrane filters (Nuclepore) with a Lipex<sup>TM</sup> extruder (Northern Lipids Inc.) at 65°C. For 173 radiolabeling of liposomes, [<sup>3</sup>H]cholesteryl hexadecyl ether (PerkinElmer Japan Co., Ltd.) was 174 mixed in the lipid/chloroform solution before the lyophilization. For fluorescence labeling of 175 liposomes, DiIC<sub>18</sub>, DiOC<sub>18</sub> or DiR was added in the same manner.

For conjugation of anti-TF antibody to the liposomal surface, DSPE-PEG-Mal was used as a linker molecule. DSPE-PEG-Mal was mixed with a solution of plain liposomes (DSPC /DSPE-PEG-Mal = 1 / 0.05 as a molar ratio), and the mixture was then incubated at 65°C for 15 min to obtain PEG-Mal-conjugated liposomes. Then, the Fab' fragment of anti-mouse TF monoclonal IgG antibody was added to the PEG-Mal-conjugated liposomes; and the reaction for 181 the coupling of the maleimide group of the lipid derivative with a thiol group of the Fab' fragment 182 was carried out overnight at 37°C. After the coupling reaction was stopped by incubation with 1

183 mM 2-mercaptoethanol for 30 min at 37°C, the anti-mouse TF antibody-conjugated liposomes

184 (TF Ab-Lip or mTF Ab-Lip) were purified by 3 cycles of ultracentrifugation (550,000 x g, 15 min,

185 4°C; CS120GXL, Hitachi Co., Ltd.). The amount of the Fab' fragment was measured by HPLC.

186 Particle size and ζ-potential of liposomes were determined with a ZetaSizer Nano ZS (Malvern

187 Instruments Ltd).

To prepare PEG-modified liposomes (PEG-Lip), we used DSPE-MPEG instead of DSPE-PEG-Mal. For control antibody-conjugated liposomes (Cont Ab-Lip), the Fab' fragment of control rat IgG antibody (Equitech-Bio Inc.) was used instead of anti-mouse TF antibody; and the modification of the liposomes was carried out in the same manner. For the preparation of antihuman TF antibody-conjugated liposomes (hTF Ab-Lip), the Fab' fragment of anti-human TF antibody was prepared and then conjugated to the liposomes. Liposomes conjugated with both anti-mouse and anti-human TF (mhTF) were also prepared as described above.

195 For doxorubicin (DOX) encapsulation into liposomes, a remote-loading method using 196 ammonium sulfate was applied. In brief, a thin lipid film was hydrated with 250 mM ammonium 197 sulfate solution; and after sizing of the liposomes, the liposomes were dialyzed against water 198 overnight to generate a pH gradient. After ultracentrifugation of the liposomes, the liposomes 199 were suspended with 20 mM HEPES buffer (pH 7.4). Then, DOX (2 mg/mL) solution was added 200 to the liposome solution; and incubation was carried out at 65°C for 1 h. Unencapsulated DOX 201 was removed by ultracentrifugation, and the pelleted liposomes were resuspended in 20 mM 202 HEPES buffer (pH 7.4). Conjugation of anti-TF antibody to the liposomes was then done as 203 described above.

204

# 205 2.8. Liposome association assay

KLN205 cells (2.0 x  $10^4$  cells/well), B16F10 cells (1.5 x  $10^4$  cells/well), NIH3T3 cells 206 (1.5 x 10<sup>4</sup> cells/well) or 2H-11 (1.5 x 10<sup>4</sup> cells/well) cells were seeded onto the wells of a poly-L-207 lysine-coated 96-well plate and incubated at 37°C overnight. After removal of the medium, the 208 209 cells were incubated in fresh medium containing DiIC<sub>18</sub>-labeled PEG-Lip, Cont Ab-Lip or TF Ab-210 Lip (DSPC concentration of 0.5 mM) for 3 or 24 h. Then, the cells were washed with PBS and 211 lysed with 0.1% SDS/Tris buffer solution (pH 7.4). To determine the association of liposomes 212 with the cells, we measured the fluorescence intensity of DiI (Ex. 549 nm; Em. 592 nm) by using 213 an Infinite M200 microplate reader (Tecan Japan Co., Ltd.). In the case of association with human tumor cell lines, fluorescently labeled hTF Ab-Lip were incubated with BxPC3 or Suit-2 cells;and the fluorescence was measured in a similar manner.

To observe the uptake of liposomes into TF-expressing tumor cells, we incubated DiIC<sub>18</sub>-labeled PEG-Lip, Cont Ab-Lip or TF Ab-Lip with KLN205 cells for 3 h at 37°C. After nuclear staining with DAPI, the fluorescence was observed with a confocal laser-scanning microscope (LSM 510 META, Carl Zeiss).

220

221 2.9. In vitro cytotoxicity assay

222 KLN205 cells (1.0 x  $10^4$  cells/well) or B16F10 cells (5.0 x  $10^3$  cells/well) were seeded 223 onto the wells of a poly-L-lysine-coated 96-well plate and cultured overnight. DOX-encapsulated 224 PEG-modified liposomes (PEG-LipDOX), DOX-encapsulated Cont Ab-Lip (Cont Ab-LipDOX) or TF Ab-LipDOX with DOX doses at 0.1, 0.5, 1, 5, 10  $\mu$ g/mL were added to the cells; and 12 h 225 226 later, the cells were washed with PBS. Then, they were cultured in fresh medium without 227 liposomes for 48 h. The viable cells were determined by performing a WST-8 assay: Cell 228 Counting Kit-8 (Dojindo Laboratory) solution was added to the medium and after a 1-h incubation 229 at 37°C, the absorbance at a wavelength at 450 nm and that of the reference one at 630 nm were 230 measured by an Infinite M200 microplate reader. To determine their cytotoxicity against human 231 pancreatic tumor BxPC2 cells, we incubated PEG-LipDOX, Cont Ab-LipDOX or DOX-232 encapsulated hTF Ab-Lip (hTF Ab-LipDOX) with the cells and evaluated the suppressive effect 233 on the tumor cell proliferation by performing the WST-8 assay.

234

# 235 2.10. Quantitative analysis of liposome accumulation in solid tumor

236 [<sup>3</sup>H]-labeled PEG-Lip, Cont Ab-Lip or TF Ab-Lip (DSPC concentration: 1 mM) were 237 intravenously injected into KLN205 tumor-bearing mice via a tail vein (74 kBq/0.2 mL/mouse). 238 Then, 3 or 24 h later the mice were sacrificed; and the plasma and solid tumor were collected. After the samples had been solubilized with Solvable<sup>™</sup> (PerkinElmer Inc.) at 50°C overnight, 239 240 the dissolved samples were subsequently mixed with Hionic-Fluor<sup>™</sup> (PerkinElmer Inc.). 241 Thereafter, the radioactivity was measured by using a liquid scintillation counter (LSC-7400, 242 Hitachi Aloka Medical, Ltd.). The distribution data were presented as the percentage of injected 243 dose per 100-mg tissue weight. The total weight of plasma was assumed to be 4.38% of the body 244 weight.

245

# 246 2.11. Intratumoral distribution of liposomes

247 DiOC<sub>18</sub> or DiR-labeled PEG-Lip, Cont Ab-Lip or TF Ab-Lip were intravenously 248 injected into KLN205 tumor-bearing mice via a tail vein; and after 24 h, their solid tumors were 249 perfused with an excess amount of PBS in order to remove the circulating liposomes in the tumor 250 vessels. The liposomes that had accumulated in the tumor tissue were imaged by use of an in vivo 251 fluorescence imaging system (IVIS Lumina, Perkin Elmer). Also, after dissection, frozen tumor 252 sections were prepared; and immunostaining was carried out as described above. The localization 253 of liposomes and stromal cells in the tumor was observed by use of a fluorescence microscope 254 (IX71, Olympus) and an LSM510META confocal laser-scanning microscope.

255

### 256 2.12. Therapeutic experiment

KLN 205 tumor cells (5 x  $10^6$  cells) were subcutaneously implanted into DBA/2 male 257 258 mice (day 0), and TF Ab-LipDOX solutions (0.2 mL) with various DOX dosages (1, 2, or 5 259 mg/kg/day) were intravenously injected via a tail vein at day 7, 10, 13, and 16 after the tumor 260 implantation. In addition, to compare the tumor-suppressive effect with that of other drug 261 formulations, we injected KLN205 tumor-bearing mice with DOX, PEG-LipDOX, Cont Ab-262 LipDOX or TF Ab-LipDOX at a DOX dosage of 5 mg/kg/day at days 6, 8, 10, 12, and 14 after 263 tumor implantation. The tumor volume and the body weight changes were monitored daily. The tumor volume was calculated according to the following formula: Tumor volume =  $0.4 \text{ x a x } b^2$ 264 265 (a; largest diameter, b; smallest diameter).

266

# 267 2.13. Human pancreatic tumor targeting experiment

BxPC3 cells (5 x  $10^6$  cells) were subcutaneously implanted into BALB/c nu/nu male mice for preparing human pancreatic tumor-bearing mice. For observation of the liposome distribution in the solid tumors, DiIC<sub>18</sub>-labeled PEG-Lip, Cont Ab-Lip, mTF Ab-Lip, hTF Ab-Lip or mhTF Ab-Lip were intravenously injected into the tumor-bearing mice via a tail vein; and after 24 h, the tumor frozen sections were prepared. Then, the sections were stained with Cy3conjugated anti- $\alpha$ -SMA antibody and DAPI; and intratumoral distribution of the DiI fluorescence was observed with the LSM510META microscope.

To determine the therapeutic effect on human pancreatic tumor, we injected DOX, PEG-LipDOX, mTF Ab-LipDOX, hTF Ab-LipDOX or DOX-encapsulated mhTF Ab-Lip (mhTF Ab-LipDOX) at a dosage of 5 mg/kg/day at days 8, 13, 18, and 23 into BxPC3 tumor-bearing mice after tumor implantation and measured the solid tumor size.

279

### 280 **3. Results**

### 281 3.1. Preparation of stroma-rich mouse tumor model

282 To select the TF-expressing tumor cells, we first examined the expression of mouse 283 TF in mouse tumor cell lines of squamous KLN205 carcinoma, B16F10 melanoma, Colon26 carcinoma, lung LLC carcinoma, and Meth A fibrosarcoma. The results indicated that the TF 284 285 expression was higher in both KLN205 and B16F10 cells than that in the other cells (Fig. 1A). 286 Additionally, when the expression of TF in non-tumor cells such as mouse fibroblast NIH3T3 287 cells and endothelial 2H-11 cells was also examined, the TF expression in the NIH3T3 cells was 288 obviously higher than that in the 2H-11 ones, suggesting that TF expression was enhanced in both 289 tumor and stromal fibroblast cells (Fig. 1A). Next, 2 kinds of tumor-bearing mice in which the 290 TF expression in the tumor cells was either high or low were prepared; and the TF expression in 291 the whole tumor tissue was compared. As the result, TF expression in the KLN205 solid tumor



#### Fig. 1. Preparation of stroma-rich mouse tumor model

(A) TF expression in tumor and non-tumorous cell lines. Mouse KLN205 squamous tumor cells, B16F10 melanoma (B16) cells, Colon26 NL-17 carcinoma (Colon26) cells, Lewis lung carcinoma (LLC) cells, Meth A fibrosarcoma cells, mouse NIH3T3 fibroblast cells, and mouse 2H-11 endothelial cells were cultured; and the expression levels of mouse TF (mTF) and  $\beta$ -actin were examined by Western blotting. (B) TF expression in solid tumors. Colon26 or KLN205 tumor cells were subcutaneously implanted into mice to prepare solid tumor-bearing mice. The amounts of expression of TF and  $\beta$ -actin in the tumors were examined, once their sizes had reached the indicated volumes. (C) Distribution of TF expression in KLN205 solid tumor. Frozen sections of the KLN205 tumor were prepared and immunostained for TF (green),  $\alpha$ -smooth muscle actin ( $\alpha$ -SMA, red) for stromal staining, and DAPI (blue) for nuclear staining. Scale bar represents 100 µm.

was significantly higher than that in the Colon26 solid tumor; and the expression increased with tumor progression (Fig. 1B). Moreover, the distribution of TF expression in the KLN205 solid tumor was confirmed by immunostaining of both TF and  $\alpha$ -SMA, the latter of which was used as a marker of stromal cells in the KLN205 solid tumor. Microscopic observation indicated that TF was widely distributed in the tumor tissue, and the factor was also expressed in many  $\alpha$ -SMApositive cells, suggesting that TF was expressed in not only the tumor cell region but also in the stromal one in the tumor tissue and indicating that the KLN205 solid tumor is a model of a stromarich tumor (Fig. 1C).

300

# 301 *3.2. Characterization of TF Ab-Lip and TF Ab-LipDOX*

302 TF Ab-Lip and TF Ab-LipDOX showed similar particle sizes and  $\zeta$ -potentials in 303 comparison with those of PEG-Lip, PEG-LipDOX, Cont Ab-Lip, and Cont Ab-LipDOX: The 304 average particle sizes of PEG-Lip, PEG-LipDOX, Cont Ab-Lip, Cont Ab-LipDOX, TF Ab-Lip, 305 and TF Ab-LipDOX were 133 nm, 132 nm, 141 nm, 145 nm, 130 nm, and 141 nm, respectively; 306 and their  $\zeta$ -potentials, -3.0 mV, -2.3 mV, -8.3 mV, -6.2 mV, -8.8 mV, and -7.3 mV, respectively. 307 The DOX encapsulation ratios for PEG-LipDOX, Cont Ab-LipDOX, and TF Ab-LipDOX were 308 86, 85, and 84%, respectively (Table S1). To evaluate the specific binding of TF Ab-Lip to the 309 target molecule, TF, we performed a liposome binding assay using the Biacore system. The results 310 indicated that only TF Ab-Lip showed a specific association with the TF-immobilized chip, 311 whereas PEG-Lip and Cont Ab-Lip had so such association (Fig. 2A). Furthermore, TF Ab-Lip 312 did not bind to BSA, suggesting that TF Ab-Lip possessed a selective binding potential for the TF 313 molecule.

314

# 315 3.3. TF-mediated uptake of TF Ab-Lip into TF-expressing cells

316 Next, a liposome association assay using mouse TF-expressing KLN 205 and B16 cells, 317 and low TF-expressing Colon26 cells was carried out: Fluorescently labeled PEG-Lip, Cont Ab-318 Lip or TF Ab-Lip was incubated with the cells for 3 or 24 h, after which the fluorescence intensity 319 in the cells was quantitatively analyzed. The results indicated that TF Ab-Lip was associated with 320 KLN205 cells in a time-dependent manner and that the association was significantly higher than 321 that observed with PEG-Lip or Cont Ab-Lip (Fig. 2B). A similar result was obtained with TF-322 expressing B16F10 cells (Fig. S2A). On the other hand, the association of liposomes into Colon26 323 cells was very low, with the association level being similar among the various types of liposomes 324 (Fig. 2B). When the liposome uptake in the cells was observed by using confocal laser-scanning 325 microscopy, the fluorescence of DiIC<sub>18</sub>-labeled TF Ab-Lip was obviously localized in the cytosol 326 of not only KLN205 cells (Fig. 2C) but also B16F10 cells (Fig. S2B), suggesting that TF-Ab-Lip 327 could target TF-expressing tumor cells and deliver ingredients into them.

Next, to evaluate the targetability of TF Ab-Lip to stromal cells, we performed a liposome association assay using NIH3T3 and 2H-11 cells. The results revealed that TF Ab-Lip were significantly associated with the TF-expressing NIH3T3 cells compared with the association 331 of PEG-Lip and Cont Ab-Lip and that the association was similar for TF-expressing KLN205 and

332 B16F10 cells (Fig. 2B, C). In contrast, the association of TF Ab-Lip into 2H-11 cells was similar

333 level to those of PEG-Lip and Cont Ab-Lip (Fig. 2B). These results suggest that TF-Ab-Lip could

target stromal fibroblast cells due to the high affinity of these liposomes for the TF molecules on

the fibroblast cell surface.



Fig. 2. Targetability of TF Ab-Lip to TF-expressing cells.

(A) Specific binding of TF Ab-Lip to mouse TF. PEG-Lip, Cont Ab-Lip or TF Ab-Lip were reacted with mouse TF- or BSAimmobilized chip, and the interaction was analyzed with the Biacore system. (B) Targeting of TF Ab-Lip to TF-expressing cells. KLN205 tumor, Colon26 tumor, NIH3T3 fibroblast or 2H-11 endothelial cells were incubated with DiIC<sub>18</sub>-labeled PEG-Lip, Cont Ab-Lip or TF Ab-Lip for 3 or 24 h at 37°C. The percentage of liposome uptake was determined by measuring the fluorescence intensity of DiI in the cells. Significant differences are shown (\*\*, P < 0.01; \*\*\*, P < 0.001, Tukey HSD). (C) Intracellular uptake of TF Ab-Lip into TF-expressing cells. KLN205 or NIH3T3 cells were incubated with DiIC<sub>18</sub>-labeled PEG-Lip, Cont Ab-Lip or TF Ab-Lip (red) for 3 h at 37°C. After nuclear staining with DAPI (blue), the fluorescence distribution was observed under a confocal laser-scanning microscope. Scale bars represent 50 µm. (D) Cytotoxicity of TF Ab-LipDOX against KLN205 tumor cells. KLN205 cells were incubated for 12 h with DOX, PEG-LipDOX, Cont Ab-LipDOX or TF Ab-LipDOX at DOX doses of 0.1, 0.5, 1, 5, 10 µg/mL; and after having been washed with PBS, the cells were additionally cultured for 48 h. The viable cells were then determined by performing a WST-8 assay.

336

# 337 3.4. Inhibitory effect of TF Ab-LipDOX on proliferation of TF-expressing tumor cells

338 To demonstrate the potential for drug delivery by TF Ab-Lip to TF-expressing cells, 339 we performed a cytotoxicity assay to examine the anti-proliferative effect of TF Ab-LipDOX 340 against the KLN205 cells. As the result, TF Ab-LipDOX significantly inhibited the proliferation 341 of KLN205 cells compared with non-targeted PEG-LipDOX or Cont Ab-LipDOX (Fig. 2D). The 342 IC<sub>50</sub> of DOX, PEG-LipDOX, Cont Ab-LipDOX, and TF Ab-LipDOX were 0.2 µg/mL, 5.8 µg/mL, 343 3.9  $\mu$ g/mL, and 1.2  $\mu$ g/mL as DOX concentration, respectively. Similar results were obtained in 344 an experiment using B16F10 cells, where the IC<sub>50</sub> values for DOX, PEG-LipDOX, Cont Ab-345 LipDOX, and TF Ab-LipDOX were 0.1  $\mu$ g/mL, 1.2  $\mu$ g/mL, 1.1  $\mu$ g/mL, and 0.3  $\mu$ g/mL, 346 respectively (Fig. S2C). These results suggested TF Ab-LipDOX to have strong anti-tumor 347 activity and indicated that TF Ab-Lip could be a useful drug carrier to target TF-expressing cells.

348

# 349 3.5. Accumulation of TF Ab-Lip in solid tumors after systemic injection

350 Next, we prepared radiolabeled PEG-Lip, Cont Ab-Lip, and TF Ab-Lip to examine the 351 biodistribution of these liposomes in KLN205 solid tumor-bearing mice after intravenous 352 injection. The results for 3-h post injection indicated that TF Ab-Lip had obviously accumulated 353 in the solid tumor and that the accumulation was significantly higher than that observed for PEG-354 Lip or Cont Ab-Lip (Fig. 3A). The retention of TF Ab-Lip in the bloodstream was quite high and 355 similar to that of long-circulating PEG-Lip, whereas that of Cont Ab-Lip was much decreased. 356 The results at 24-h post injection indicated that the accumulation of TF Ab-Lip in the solid tumor 357 increased with time. Additionally, the high accumulation of fluorescently labeled liposomes in the 358 tumor could be imaged by IVIS (Fig. 3B). When the intratumoral distribution of TF Ab-Lip was 359 observed, TF Ab-Lip was found to be located in not only the peripheral region but also the internal 360 area of the KLN205 solid tumor, thus widely distributed in the whole tumor tissue (Fig. 3C). In 361 contrast, the distribution of PEG-Lip and Cont Ab-Lip was limited to only a small part of the 362 tumor tissue (Fig. 3C). Furthermore, to determine the region of the distributed liposomes in detail, 363 we immunostained tumor sections. The results showed that TF Ab-Lip were found not only in the 364  $\alpha$ -SMA-positive stromal region but also in the surrounding tumor cell region in the tumor sections, 365 indicating that TF Ab-Lip was distributed to both tumor cells and stromal cells in the tumor tissue 366 (Fig. 3D). These findings suggest that TF Ab-Lip could actively target both TF-expressing tumor 367 and stromal cells via the binding of anti-TF antibody on the liposomal surface to the TF on these 368 cells, thus suggesting the possibility for effective delivery of encapsulated drugs to stroma-rich 369 tumors by this tumor dual targeting approach.

- 370
- 371



#### Fig. 3. Stroma-rich tumor targeting by TF Ab-Lip

(A) Quantitative analysis of liposome accumulation in KLN205 solid tumors. Radiolabeled PEG-Lip, Cont Ab-Lip or TF Ab-Lip were intravenously injected into KLN205 solid tumor-bearing mice via a tail vein; and the liposomes were allowed to be distributed for 3 or 24 h. After collecting the plasma and solid tumor, the radioactivity was measured by a liquid scintillation counter. Data are presented as the percentage of the injected dose per 100-mg tissue weight. Significant differences are shown with asterisks (\*, P < 0.05; \*\*, P < 0.01; \*\*\*, P < 0.001, Tukey HSD). (B, C) Fluorescence imaging of distribution of TF Ab-Lip in KLN205 solid tumors. DiR-labeled PEG-Lip, Cont Ab-Lip or TF Ab-Lip were intravenously injected into KLN205 tumor-bearing mice and allowed to circulate for 24 h. After blood perfusion with PBS, the solid tumors were harvested; and the fluorescence was thereafter scanned with an IVIS system (B). Then, frozen sections were prepared; and nuclei were stained with DAPI (blue). Distribution of DiR fluorescence (red) was observed with a fluorescence microscope (C). White-dotted lines represent the tumor border in the sections. Scale bars represent 500 µm. (D) Intratumoral distribution of TF Ab-Lip in KLN205 solid tumors. DiOC<sub>18</sub>-labeled PEG-Lip, Cont Ab-Lip or TF Ab-Lip were intravenously injected into KLN205 tumor-bearing mice. After 24 h, each solid tumor was harvested and tumor sections prepared. Immunofluorescence staining of  $\alpha$ -SMA by using Cy3-conjugated anti- $\alpha$ -SMA antibody (red) was performed to visualize the stromal cells. Nuclei were stained by DAPI (blue). Then, the fluorescence images of the sections were observed. Scale bars represent 100 µm.

372373

### 374 3.6. Therapeutic effect of TF Ab-LipDOX on growth of KLN205 solid tumors

To demonstrate the impact of our targeting strategy on stroma-rich tumor therapy, we evaluated the tumor-suppressive effect of TF Ab-LipDOX on KLN205 solid tumor growth. KLN205 tumor-bearing mice were intravenously injected with TF Ab-LipDOX at the indicated dosages as DOX via a tail vein; and the tumor volume after 4 treatments, with 1 given every 2 days, was measured. The results indicated that the growth of the KLN205 solid tumors was strongly suppressed by the fourth treatment with TF Ab-LipDOX and that the suppression was



Fig. 4. Cancer chemotherapy of stroma-rich KLN205 tumors with TF Ab-LipDOX. (A) Dosage-dependent suppression of KLN205 tumor growth by the treatment with TF Ab-LipDOX. KLN205 tumor-bearing mice were intravenously injected with PBS or TF Ab-LipDOX (1, 2 or 5 mg/kg/day as DOX dosage) at day 7, 10, 13, and 16 after the tumor implantation; and the tumor volume was monitored. Black arrows show the days of sample injection. (B) Comparison of therapeutic effect of liposomal DOX formulations on the growth of KLN205 solid tumors. KLN205 tumor-bearing mice were intravenously injected with PBS, DOX, PEG-LipDOX, Cont Ab-LipDOX or TF Ab-LipDOX (5 mg/kg/day as DOX dose) at day 6, 8, 10, 12, and 14 after tumor implantation. Body weight changes of the mice were observed in each experiment. Data are shown as the mean  $\pm$  S.D. Significant differences are shown with symbols (\*; P < 0.05, \*\*; P < 0.01, \*\*\*; P < 0.001 vs. PBS, #; P < 0.05, Tukey HSD).

dependent on the DOX dosage (Fig. 4A). Then, this anti-tumor effect of TF Ab-LipDOX on the
 KLN205 tumor-bearing mice was compared with that of DOX, PEG-LipDOX, and Cont Ab-

- 383 LipDOX. Consequently, the treatments with TF Ab-LipDOX significantly suppressed the tumor
- 384 growth; and the effect was stronger than that found for the other treatment groups (Fig. 4B). As a
- 385 result of this tumor-suppressive effect, the survival time of the tumor-bearing mice was prolonged

386 in the TF Ab-LipDOX-treated group: The survival-time ratio for the tumor-bearing mice treated 387 with DOX, PEG-LipDOX, Cont Ab-LipDOX, and TF Ab-LipDOX against PBS-treated group 388 was 153, 196, 181, and 220%, respectively. Furthermore, when the body weight of the tumor-389 bearing mice was monitored as an indicator of side effects, little change was observed in any of 390 the treated groups (Fig. 4A, B). These results suggest that TF Ab-LipDOX could be useful for the 391 treatment of refractory stroma-rich tumors such as pancreatic tumors without causing severe side 392 effects.

393

394

# 3.7. Targetability of TF Ab-Lip to human pancreatic tumor

395 To demonstrate the applicability of anti-TF antibody-conjugated liposomes to stroma-396 rich human pancreatic tumor targeting, we chose 2 human pancreatic tumor cell lines, BxPC3 and 397 Suit-2, and first compared the expression of human TF in both cell lines. The results of Western 398 blotting analysis indicated that the expression of human TF in BxPC3 cells was quite higher than 399 that in the Suit-2 cells (Fig. 5A), and so we decided to use BxPC3 tumors as a model of human 400 TF-expressing pancreatic tumors. BxPC3 solid tumor-bearing mice were prepared by 401 subcutaneously implanting the tumor cells into nude mice, and TF expression in the solid tumor 402 was confirmed. The histochemical analysis by HE staining indicated that these solid tumors had 403 a rich stromal region in the tumor tissue (Fig. 5B). Furthermore, as the results of immunostaining 404 of tumor sections, human TF was expressed in EpCAM-positive tumor cells, but not in α-SMA-405 positive stromal cells. In contrast, mouse TF was expressed only in the α-SMA-positive stromal 406 cells (Fig. 5C). These results suggest that BxPC3 tumor-bearing mice expressed human TF in the 407 tumor cell region and mouse TF in the stromal region of the tumor tissue.

408 Next, to investigate the capability of TF Ab-Lip to target human pancreatic tumors and 409 to confirm the usefulness of the targeting approach for the treatment of BxPC3 solid tumors, we 410 prepared liposomes conjugated with anti-human TF antibody (hTF Ab-Lip), anti-mouse TF 411 antibody (mTF Ab-Lip) or both anti-hTF and mTF antibodies (mhTF Ab-Lip; Fig. S3A). When 412 the binding and uptake of hTF Ab-Lip to BxPC3 and Suit-2 tumor cells was examined, hTF Ab-413 Lip were significantly associated with the high TF-expressing BxPC3 cells compared with the 414 association of non- targeted PEG-Lip and Cont Ab-Lip with these cells, but and associated to a 415 lesser degree with the low TF-expressing Suit-2 cells (Fig. 5D). In addition, the association of 416 hTF Ab-Lip with mouse NIH3T3 was low and similar to that of PEG-Lip or Cont Ab-Lip. 417 Furthermore, when the in vitro cytotoxicity of hTF Ab-LipDOX against BxPC3 cells was 418 examined, hTF Ab-LipDOX dominantly inhibited the proliferation of the tumor cells compared

419 with PEG-LipDOX and Cont Ab-LipDOX, with the IC<sub>50</sub> values of DOX, PEG-LipDOX, Cont 420 Ab-LipDOX, and hTF Ab-LipDOX being 0.06 µg/mL, 3.9 µg/mL, 3.0 µg/mL, and 1.5 µg/mL 421 (Fig. 5E). These results suggest that hTF Ab-Lip enabled the targeting of human TF-expressing 422 BxPC3 tumor cells, but not mouse TF-expressing cells. Then, we observed the intratumoral 423 distribution of anti-TF antibody-conjugated liposomes in BxPC3 solid tumor and compared it 424 with that obtained with PEG-Lip, Cont Ab-Lip, mTF Ab-Lip, hTF Ab-Lip, and mhTF Ab-Lip. 425 Consequently, mhTF Ab-Lip, targeting both human TF and mouse TF, was widely distributed in 426 the whole tumor tissue and localized in not only the  $\alpha$ -SMA-positive mouse stromal region, but also in the other α-SMA-negative region, which was mainly composed of human BxPC3 tumor 427 428 cells (Fig. 5F). On the other hand, hTF Ab-Lip accumulated in the α-SMA-negative tumor cell 429 region, but not in the a-SMA-positive mouse stromal region; and mTF Ab-Lip showed low 430 accumulation in the tumor tissue, but a portion of them was localized in the  $\alpha$ -SMA-positive 431 mouse stromal region. Finally, we carried out the therapeutic experiment using BxPC3 tumor-432 bearing mice and examined anti-pancreatic tumor effect of mhTF Ab-LipDOX enables to target 433 both mouse TF-expressing tumor stromal cells and human TF-expressing tumor cells on mouse 434 stroma-rich human tumor. The result showed that mhTF Ab-LipDOX significantly suppressed the 435 growth of BxPC3 tumor and the tumor-suppressive effect was highest in the treated groups (Fig. 436 5G). These results strongly suggest that TF targeting by anti-TF antibody-conjugated liposomes 437 can provide drug delivery to TF-expressing stroma-rich tumors and that TF-targeting drug 438 delivery strategy is useful for the treatment of human stroma-rich pancreatic tumors. 439





(A) TF expression in human pancreatic tumor cells. The expression levels of human TF and β-actin in human pancreatic BxPC3 or Suit-2 cells were examined by Western blotting. (B) Histological analysis of BxPC3 solid tumors. Paraffin sections of BxPC3 solid tumors were prepared and stained with H&E. Scale bars represent 200 µm. (C) Expression of TF in BxPC3 solid tumors. Frozen sections of the BxPC3 solid tumor were prepared and fluorescently stained for human TF, mouse TF, α-SMA, or EpCAM to visualize the stromal cells or tumor cells, respectively. Nuclei were stained with DAPI. Scale bars: 100 µm. (D) Targeting of hTF Ab-Lip to hTF-expressing tumor cells. BxPC3 cells, SUIT-2 cells or NIH3T3 cells were incubated with DilC18-labeled PEG-Lip, Cont Ab-Lip or hTF Ab-Lip for 24 h at 37°C. After the cells had been washed with PBS, the amount of liposome association with the cells was determined by measuring the fluorescence intensity. Data are shown as the mean of uptake (%) and the S.D. Significant differences are shown with asterisk (\*: P < 0.05, \*\*: P < 0.01, Tukey HSD). (E) BxPC3 cells were incubated with DOX, PEG-LipDOX, Cont Ab-LipDOX or TF Ab-LipDOX at 37°C for 12 h. After a washing of the cells with PBS, the cells were cultured in fresh medium for 48 h. Then, cell viability was determined by performing a WST-8 assay. Data are shown as the mean of viability (%) and S.D. (F) Intratumoral distribution of TF Ab-Lip in BxPC3 solid tumors. DiOC18 (green)-labeled PEG-Lip, Cont Ab-Lip, anti-mouse TF antibody-conjugated liposomes (mTF Ab-Lip), anti-human TF antibody-conjugated liposomes (hTF Ab-Lip), or both anti-mouse and anti-human TF antibody-conjugated liposomes (mhTF Ab-Lip) were intravenously injected into BxPC3 tumor-bearing mice. Twentyfour hours after the injection, frozen sections of the tumor tissue were prepared. Immunofluorescence staining of mouse a-SMA (red) was performed to visualize tumor-associated stromal cells. Nuclei were stained by DAPI (blue). The fluorescence images of the sections were observed by using a confocal laser-scanning microscope. Scale bars represent 100 µm. (G) Suppressive effect of DOX-encapsulated TF Ab-Lip on BxPC3 solid tumor growth. BxPC3 tumor-bearing mice were intravenously injected with PBS, DOX, PEG-LipDOX, DOX-encapsulated mTF Ab-Lip (mTF Ab-LipDOX), hTF Ab-Lip (hTF Ab-LipDOX) or mhTF Ab-Lip (mhTF Ab-LipDOX) (5 mg/kg/day as DOX dose) via a tail vein at day 8, 13, 18, and 23 after tumor implantation. Data are shown as the mean  $\pm$  S.D. Significant differences are shown (\*; P < 0.05 vs. PBS, #; P< 0.05, Tukey HSD).

441

442

### 443 **4. Discussion**

444 Formation of tumor stroma is regulated by certain cytokines, and especially TGF- $\beta$  is 445 a representative of such molecules [2]: TGF- $\beta$  is secreted from tumor cells and tumor-associated 446 macrophages and stimulates fibroblast cells, which in turn then express certain molecules such as 447 α-SMA. These activated fibroblasts, referred to as tumor-associated fibroblasts, begin to 448 proliferate to form a thick stroma composed of collagen molecules, resulting in a collagen 449 network between tumor cells and the stroma [13]. This microenvironment-formation event is very 450 important for both tumor cell growth and acquisition of drug resistance by the tumor. In fact, the 451 pancreatic tumor, a representative stroma-rich tumor, is a malignancy that acquires drug resistance 452 due to poor delivery of anti-cancer drugs to the tumor tissue [14]. To improve the therapeutic 453 effect of drugs on pancreatic tumors, several approaches using DDS medicines have been 454 developed [5, 15]. Among them, our collaborator Matsumura has advocated a novel cancer 455 therapeutic concept, called cancer stromal targeting (CAST), which is a stroma-targeting strategy 456 that enables a drug concentration to be enhanced in stroma-rich tumor tissues, thereby 457 eradicating the tumor cells indirectly [16]. Actually, they developed an anti-insoluble fibrin 458 antibody as a targeting probe for tumor stromal cells [17] and demonstrated the potential usages 459 of the CAST approach for pancreatic cancer therapy [18] and diagnosis [19]. TF is another 460 suitable candidate molecule for CAST, since TF is normally expressed in the extravascular stroma 461 of normal tissues [20]. Additionally, it has been reported that stimulation of fibroblast cells with 462 TGF- $\beta$  increases the expression of TF in the tumor stroma [10]. Besides, TF expression is 463 enhanced in certain kinds of tumor cells, because the binary complex of TF and factor VII on the 464 membrane of tumor cells promotes tumor cell growth, migration, survival, and angiogenic 465 stimulation via activation of the protease-activated receptor (PAR)-2 [21, 22]. Our presently 466 presented strategy for the treatment of stroma-rich tumors is to enhance liposome delivery via TF 467 targeting in both tumor cells and tumor stromal cells. In the experiments using cultured cell lines, 468 we found that TF was highly expressed in KLN205 and B16 tumor cells, and non-tumorous 469 NIH3T3 fibroblast cells, but poorly expressed in Colon26 tumor cells and 2H-11 endothelial cells 470 (Fig. 1A). Reflecting this result, TF expression was obviously observed in the KLN205 solid 471 tumor, but was quite low in Colon26 solid tumor (Fig. 1B). Furthermore, the TF expression was 472 observed not only in the  $\alpha$ -SMA-negative, but also in the  $\alpha$ -SMA-positive, region and distributed 473 throughout the KLN205 tumor tissue (Fig. 1D). We also found that the expression of  $\alpha$ -SMA in 474 the KLN205 tumor was evident in the non-tumorous EpCAM-negative region around CD31-475 positive blood vessels (Fig. S1A), indicating that the KLN205 solid tumor had a rich stroma. In 476 contrast, the expression of  $\alpha$ -SMA was colocalized with CD31-positive blood vessels in the low 477 TF-expressing Colon26 solid tumor (Fig. S1B), indicating that the Colon26 solid tumor consisted 478 mostly of the tumor cells and that  $\alpha$ -SMA was expressed in the vascular smooth muscle cells. 479 These data suggest that TF was expressed in not only tumor cells, but also tumor stromal cells in 480 the KLN205 tumor, making TF a promising and suitable target molecule for drug delivery to 481 stroma-rich tumors.

482 To achieve the active targeting of liposomes via the TF molecule, we prepared PEG-483 modified liposomes conjugated with anti-TF antibody on the tip of the PEG chain as a drug 484 carrier; since an antibody has the potential to strongly and specifically recognize a target molecule. 485 PEG-modified liposomes pre-sized to less than 200 nm in diameter passively accumulate in 486 angiogenic vessel-rich solid tumors after systemic injection via the enhanced permeability and 487 retention (EPR) effect, which provides a major mechanism of tumor targeting by drug 488 nanocarriers [23]. Our previous study demonstrated that modification of angiogenic vessel-489 targetable peptide on the tip of PEG chains of PEG-modified liposomes is suitable for recognition 490 of target molecules [24], because long-time circulation of liposomes in the bloodstream by PEG 491 modification enhances the chance for interaction between the targeting probe with the targeted 492 molecule on the surface of angiogenic endothelial cells as well as accumulation in the tumor by 493 the EPR effect [25]. Particle sizes of prepared TF Ab-Lip and TF Ab-LipDOX were less than 150 494 nm and quite similar to those of PEG-Lip, Cont Ab-Lip, PEG-LipDOX, and Cont Ab-LipDOX, 495 suggesting that they could be expected to not only demonstrate the EPR effect but also actively 496 target the TF-expressing tumors. Actually, TF-Ab-Lip was significantly taken up into high TF-497 expressing tumor cells and fibroblast cells, but not into low-TF-expressing tumor cells and 498 endothelial cells (Fig. 2B). Furthermore, high accumulation of TF-Ab-Lip in the KLN205 solid 499 tumor occurred after the systemic injection into tumor-bearing mice following long-time 500 circulation in the bloodstream, as was also observed with PEG-Lip (Fig. 3A). Notably, TF Ab-501 Lip was distributed throughout the tumor tissue and retained in the tissue after the blood had been 502 washed out of the tumor by perfusion with PBS; whereas almost all of the PEG-Lip and Cont Ab-503 Lip in the tumor tissue were washed out by the perfusion (Fig. 3C). Moreover, TF Ab-Lip 504 accumulated in both the  $\alpha$ -SMA-positive stromal region as well as in the tumor cell region (Fig. 505 3D). These lines of evidence proved the targeting capability of TF Ab-Lip and the improvement 506 of drug delivery to stroma-rich tumors following cellular uptake of the liposomes. In fact, we 507 demonstrated the potent therapeutic effect of TF Ab-LipDOX on stroma-rich KLN205 tumor 508 growth (Fig. 4).

509 To demonstrate the targeting capability of TF-targeted liposomes in detail, we carried 510 out unique experiments using human pancreatic BxPC3 tumor-bearing mice. The BxPC3 tumor 511 contained rich stroma; and immunostaining of tumor sections showed that the expression of 512 human TF in the EpCAM-positive tumor cell region but not in the α-SMA-positive stromal region, 513 whereas mouse TF was expressed in the α-SMA-positive stromal one (Fig. 5B, C). Then, human 514 TF-targetable liposomes were prepared by modification of PEG-conjugated liposomes with anti-515 human TF antibody (Fig. S3). hTF Ab-Lip were significantly taken up into BxPC3 cells (high 516 hTF-expressing), but not into Suit-2 (low hTF-expressing) or NIH3T3 cells, suggesting that hTF 517 Ab-Lip could target only human TF-expressing tumor cells (Fig. 5D). To demonstrate the utility 518 of our targeting strategy for effective drug delivery to the human pancreatic tumors and prove our 519 present research concept, we analyzed the intratumoral distribution of both mouse TF- and human 520 TF-targetable liposomes after systemic injection into BxPC3 tumor-bearing mice. Consequently, 521 mhTF Ab-Lip were located at both mouse TF-expressing stromal region and human TF-522 expressing tumor cell region in the tumor tissue, suggesting that the TF-targetable liposomes can 523 be applicable for the treatment of stroma-rich human pancreatic tumors. Kataoka and his 524 colleagues previously demonstrated the potential usage of anti-human TF antibody to deliver 525 micellar nanoparticles loaded with epirubicin or siRNA to human TF-expressing BxPC3 tumors 526 for human pancreatic cancer therapy [26, 27]. Also, our collaborator Matsumura et al. used 527 antibody-drug conjugate (ADC) drug for pancreatic tumor imaging [28], since the anti-human TF 528 antibody enables recognition of human TF molecules on the pancreatic tumor cells. Our targeting 529 DDS strategy is the combination of conventional tumor cell targeting with CAST via the TF 530 molecule: Liposomes accumulated in tumor tissue by the EPR effect can recognize both TF-531 expressing tumor cells and TF-expressing stromal cells via anti-TF antibody and are taken up into 532 both cells. The importance of stromal targeting in the treatment of stroma-rich tumors has already 533 been reported by some researchers. For example, Huang et al. recently demonstrated that systemic 534 injection of quercetin phosphate nanoparticles reduced the number of  $\alpha$ -SMA-positive fibroblasts 535 via the inhibition of Wnt16 expression and showed their suppressive effect on the growth of 536 stroma-rich bladder tumor in combination with cisplatin nanoparticle treatment [29, 30]. Also, 537 Zhou et al. focused on sonic hedgehog (SHH) signaling, which is strongly involved in the 538 interaction between pancreatic tumor cells and activated fibroblast cells, and demonstrated that 539 synergistic combination of an SHH inhibitor, GDC-0449, with PEGylated liposomal DOX 540 exhibited potent antitumor efficacy toward BxPC3 tumor growth [31]. These lines of evidence 541 strongly support the validity of our targeting DDS strategy with anti-TF antibody-conjugated

542 liposomes for the treatment of pancreatic tumors. Actually, we demonstrated the importance of 543 both targeting of tumor and tumor stromal cells in the treatment of stroma-rich pancreatic tumors 544 for the first time by performing the therapeutic experiment using BxPC3 tumor model (Fig. 5G): 545 Only mhTF Ab-LipDOX could target and damage both mouse TF-expressing stroma cells and 546 human TF-expressing pancreatic BxPC3 cells. In current clinical situation of cancer 547 chemotherapy, application of targeted delivery system with ligand-conjugated drug carriers has 548 not yet been mainstream, despite the defined therapeutic outcomes are being achieved in basic 549 researches with animal models. It is no doubt that the EPR effect is a principle concept of 550 macromolecule delivery to solid tumors, however tumor microenvironment varies according to 551 the type of tumors and the existence of thick stroma in tumor tissue is one of the reasons why the 552 DDS drugs failed to produce the EPR effect and to reach tumor cells. Our targeted strategy with 553 anti-TF antibody-modified liposomes could overcome the poor drug delivery of macromolecules 554 to stroma-rich tumors by targeting both tumor cells and stromal cells and breaking the barrier of 555 stroma.

556

# 557 **5.** Conclusion

In the present study, we demonstrated that TF Ab-Lip improved the anti-cancer drug delivery to stroma-rich tumors by active targeting of both tumor cells and tumor stromal cells via the strong interaction of liposome-surface anti-TF antibody with cell-surface TF molecules (Fig. 6). We believe that this targeting DDS strategy would be applicable for the treatment of stromarich malignant tumors including pancreatic tumors.



| Vascular endothelial cell 🛛 📁 Neovascular endothelial cell 斗 🕰 Pericyte 🐞 Macrophage

Fig. 6. Tumor cell and tumor stromal targeting with anti-TF antibody-modified liposomes

Stroma-rich tumors such as pancreatic tumors are malignant and acquire their drug resistance due to poor delivery of anticancer drugs to the tumor tissue due to the fact that the thick stroma region surrounding the tumor cells prevents drugs from gaining access to the tumor cells. The present targeting DDS strategy can solve this problem by targeting not only tumor cells but also the tumor stroma including activated fibroblast cells with a liposomal probe targeting both tumor and stromal cells. As a result, potent cancer therapy of these stroma-rich tumors can be achieved. TF is a suitable molecule for immuno-targeting both tumor and stromal cells, since TF is highly expressed in both kinds of cells. Thus, anti-TF antibody-conjugated liposome is an applicable drug carrier to treat stroma-rich tumors.

- 563
- 564

## 565 Acknowledgements

- 566 This research was supported in part by National Cancer Center Research and 567 Development Fund (29-A-9 to Y.M.) and University of Shizuoka.
- 568

# 569 **Conflict of interest**

- 570 Yasuhiro Matsumura is a Co-founder and a stock holder of RIN Institute Inc. The other 571 authors declare that there are no conflicts of interest.
- 572

### 573 References

- 574 [1] P.C. Benias, R.G. Wells, B. Sackey-Aboagye, H. Klavan, J. Reidy, D. Buonocore, M.
  575 Miranda, S. Kornacki, M. Wayne, D.L. Carr-Locke, N.D. Theise, Structure and distribution
  576 of an unrecognized interstitium in human tissues, Sci. Rep. 8 (2018) 4947.
- 577 [2] P. Papageorgis, T. Stylianopoulos, Role of tgfbeta in regulation of the tumor
  578 microenvironment and drug delivery (review), Int. J. Oncol. 46 (2015) 933-943.

- 579 [3] L. Caja, F. Dituri, S. Mancarella, D. Caballero-Diaz, A. Moustakas, G. Giannelli, I. Fabregat,
  580 Tgf-beta and the tissue microenvironment: Relevance in fibrosis and cancer, Int. J. Mol. Sci.
  581 19 (2018) 1294.
- 582 [4] D. von Ahrens, T.D. Bhagat, D. Nagrath, A. Maitra, A. Verma, The role of stromal cancer583 associated fibroblasts in pancreatic cancer, J. Hematol. Oncol. 10 (2017) 76.
- 584 [5] P.P. Adiseshaiah, R.M. Crist, S.S. Hook, S.E. McNeil, Nanomedicine strategies to overcome
  585 the pathophysiological barriers of pancreatic cancer, Nat. Rev. Clin. Oncol. 13 (2016) 750586 765.
- 587 [6] H.F. Dvorak, Tumors: Wounds that do not heal. Similarities between tumor stroma 588 generation and wound healing, N. Engl. J. Med. 315 (1986) 1650-1659.
- 589 [7] P.D. Stein, A. Beemath, F.A. Meyers, E. Skaf, J. Sanchez, R.E. Olson, Incidence of venous
  590 thromboembolism in patients hospitalized with cancer, Am. J. Med. 119 (2006) 60-68.
- 591 [8] Y. Matsumura, M. Kimura, T. Yamamoto, H. Maeda, Involvement of the kinin-generating
  592 cascade in enhanced vascular permeability in tumor tissue, Jpn. J. Cancer Res. 79 (1988)
  593 1327-1334.
- 594 [9] H.F. Dvorak, Vascular permeability factor/vascular endothelial growth factor: A critical
  595 cytokine in tumor angiogenesis and a potential target for diagnosis and therapy, J. Clin. Oncol.
  596 20 (2002) 4368-4380.
- 597 [10] J.A. Vrana, M.T. Stang, J.P. Grande, M.J. Getz, Expression of tissue factor in tumor stroma
  598 correlates with progression to invasive human breast cancer: Paracrine regulation by
  599 carcinoma cell-derived members of the transforming growth factor beta family, Cancer Res.
  600 56 (1996) 5063-5070.
- [11] Y. Saito, Y. Hashimoto, J. Kuroda, M. Yasunaga, Y. Koga, A. Takahashi, Y. Matsumura, The
  inhibition of pancreatic cancer invasion-metastasis cascade in both cellular signal and blood
  coagulation cascade of tissue factor by its neutralisation antibody, Eur. J. Cancer 47 (2011)
  2230-2239.
- [12] T.M. Allen, P.R. Cullis, Liposomal drug delivery systems: From concept to clinical
  applications, Adv Drug Deliv Rev 65 (2013) 36-48.
- [13] L. Narunsky, R. Oren, F. Bochner, M. Neeman, Imaging aspects of the tumor stroma with
  therapeutic implications, Pharmacol. Ther. 141 (2014) 192-208.
- 609 [14] B. Uzunparmak, I.H. Sahin, Pancreatic cancer microenvironment: A current dilemma, Clin
  610 Transl Med 8 (2019) 2.
- 611 [15] L. Miao, L. Huang, Exploring the tumor microenvironment with nanoparticles, Cancer Treat.

- 612 Res. 166 (2015) 193-226.
- 613 [16] Y. Matsumura, Cancer stromal targeting (cast) therapy, Adv Drug Deliv Rev 64 (2012) 710614 719.
- [17] Y. Hisada, M. Yasunaga, S. Hanaoka, S. Saijou, T. Sugino, A. Tsuji, T. Saga, K. Tsumoto, S.
  Manabe, J. Kuroda, J. Kuratsu, Y. Matsumura, Discovery of an uncovered region in fibrin
  clots and its clinical significance, Sci. Rep. 3 (2013) 2604.
- [18] M. Yasunaga, S. Manabe, A. Tsuji, M. Furuta, K. Ogata, Y. Koga, T. Saga, Y. Matsumura,
  Development of antibody-drug conjugates using dds and molecular imaging, Bioengineering
  (Basel) 4 (2017) 78.
- [19] H. Fuchigami, S. Manabe, M. Yasunaga, Y. Matsumura, Chemotherapy payload of antiinsoluble fibrin antibody-drug conjugate is released specifically upon binding to fibrin, Sci.
  Rep. 8 (2018) 14211.
- [20] H.H. Versteeg, M.P. Peppelenbosch, C.A. Spek, The pleiotropic effects of tissue factor: A
  possible role for factor viia-induced intracellular signalling?, Thromb. Haemost. 86 (2001)
  1353-1359.
- [21] E. Camerer, W. Huang, S.R. Coughlin, Tissue factor- and factor x-dependent activation of
  protease-activated receptor 2 by factor viia, Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 52555260.
- [22] M.Z. Wojtukiewicz, D. Hempel, E. Sierko, S.C. Tucker, K.V. Honn, Protease-activated
  receptors (pars)--biology and role in cancer invasion and metastasis, Cancer Metastasis Rev.
  34 (2015) 775-796.
- [23] Y. Matsumura, H. Maeda, A new concept for macromolecular therapeutics in cancer
  chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent
  smancs, Cancer Res. 46 (1986) 6387-6392.
- [24] T. Sugiyama, T. Asai, Y.M. Nedachi, Y. Katanasaka, K. Shimizu, N. Maeda, N. Oku,
  Enhanced active targeting via cooperative binding of ligands on liposomes to target receptors,
  PLoS One 8 (2013) e67550.
- [25] N. Maeda, Y. Takeuchi, M. Takada, Y. Sadzuka, Y. Namba, N. Oku, Anti-neovascular therapy
  by use of tumor neovasculature-targeted long-circulating liposome, J. Control. Release 100
  (2004) 41-52.
- [26] A. Sugaya, I. Hyodo, Y. Koga, Y. Yamamoto, H. Takashima, R. Sato, R. Tsumura, F. Furuya,
  M. Yasunaga, M. Harada, R. Tanaka, Y. Matsumura, Utility of epirubicin-incorporating
  micelles tagged with anti-tissue factor antibody clone with no anticoagulant effect, Cancer

- 645 Sci. 107 (2016) 335-340.
- [27] H.S. Min, H.J. Kim, J. Ahn, M. Naito, K. Hayashi, K. Toh, B.S. Kim, Y. Matsumura, I.C.
  Kwon, K. Miyata, K. Kataoka, Tuned density of anti-tissue factor antibody fragment onto
  sirna-loaded polyion complex micelles for optimizing targetability into pancreatic cancer
  cells, Biomacromolecules 19 (2018) 2320-2329.
- 650 [28] Y. Koga, S. Manabe, Y. Aihara, R. Sato, R. Tsumura, H. Iwafuji, F. Furuya, H. Fuchigami, Y.
- Fujiwara, Y. Hisada, Y. Yamamoto, M. Yasunaga, Y. Matsumura, Antitumor effect of
  antitissue factor antibody-mmae conjugate in human pancreatic tumor xenografts, Int. J.
  Cancer 137 (2015) 1457-1466.
- [29] L. Miao, Y. Wang, C.M. Lin, Y. Xiong, N. Chen, L. Zhang, W.Y. Kim, L. Huang,
  Nanoparticle modulation of the tumor microenvironment enhances therapeutic efficacy of
  cisplatin, J. Control. Release 217 (2015) 27-41.
- [30] K. Hu, L. Miao, T.J. Goodwin, J. Li, Q. Liu, L. Huang, Quercetin remodels the tumor
  microenvironment to improve the permeation, retention, and antitumor effects of
  nanoparticles, ACS Nano 11 (2017) 4916-4925.
- [31] Q. Zhou, Y. Zhou, X. Liu, Y. Shen, Gdc-0449 improves the antitumor activity of nanodoxorubicin in pancreatic cancer in a fibroblast-enriched microenvironment, Sci. Rep. 7
  (2017) 13379.

663

# Supplementary data

	Particle Size (nm)	PDI	ζ-Potential (mV)	Antibody (μg/mL)
PEG-modified liposome (PEG-Lip)	133 ± 16	0.15 ± 0.06	-3.0 ± 2.9	Not applicable
Control Ab-modified liposome (Cont Ab-Lip)	141 ± 15	0.17 ± 0.07	-8.3 ± 1.2	400 ± 35
Anti-mTF Ab-modified liposome (TF Ab-Lip)	130 ± 6	0.16 ± 0.08	-8.8 ± 1.4	309 ± 24

# Table S1. Formulation characteristics of TF-modified liposomes

	Particle size (nm)	PDI	ζ-Potential (mV)	DOX (µg/mL)
PEG-modified liposomal DOX (PEG-LipDOX)	132 ± 18	0.12 ± 0.06	-2.3 ± 1.6	430 ± 44
Control Ab-modified liposomal DOX (Cont Ab-LipDOX)	145 ± 25	0.15 ± 0.08	- 6.2 ± 1.3	425 ± 62
Anti-mTF Ab-modified liposomal DOX (TF Ab-LipDOX)	141 ± 12	0.12 ± 0.08	-7.3 ± 1.9	419 ± 60

The liposome solution was diluted with PBS, and the particle size and  $\zeta$ -potential were measured by use of a Zetasizer Nano system. Ab: antibody; DOX: doxorubicin; PDI: polydispersity index.





KLN205 cells (5 x  $10^6$  cells/mouse) or Colon26 NL-17 (Colon26) cells (1 x  $10^6$  cells/mouse) were implanted subcutaneously into DBA/2 or BALB/c mice, respectively to prepare tumor-bearing mice. Then, the solid tumors were collected, and the frozen sections of the tumors were prepared. (A) Immunofluorescence staining of  $\alpha$ SMA (red), EpCAM (green) or CD31 (green) was performed to visualize tumor-associated stromal cells, tumor cells or blood vessels, respectively, in the KLN205 tumor. (B) For comparison of the tumor microenvironment between KLN205 and C26NL17 solid tumors, immunofluorescence staining of  $\alpha$ SMA (red) and CD31 (green) was performed. Fluorescent images of the tumor sections were observed by using a confocal laser-scanning microscope. Scale bars represent 100 µm.



Fig. S2. Targetability of TF Ab-Lip to TF-expressing B16F10 tumor cells.

(A) Quantitative analysis of liposome association with B16F10 cells. Mouse melanoma B16F10 cells were incubated with DiIC<sub>18</sub>-labeled PEG-Lip, Cont Ab-Lip or mTF Ab-Lip for 3 or 24 h at 37°C. After the cells had been washed with PBS, they were solubilized with 0.1% SDS solution. The amount of liposomes associated with the cells was determined by measuring the fluorescence intensity. Data are shown as the mean of uptake (%) and the S.D. Significant differences are shown with asterisks (\*\*: P < 0.01, \*\*\*: P < 0.001). (B) Intracellular uptake of TF Ab-Lip into B16F10 cells. After incubation of the cells with DiIC<sub>18</sub>-labeled PEG-Lip, Cont Ab-Lip or mTF Ab-Lip for 3 h, the cells were fixed with 4% paraformaldehyde, after which the nuclei were stained with DAPI. Intracellular uptake of the liposomes was observed by confocal laser scanning microscopy. Scale bars represent 50 µm. (C) B16F10 cells were incubated with doxorubicinencapsulated PEG-Lip (PEG-LipDOX,  $\Box$ ), Cont Ab-Lip (Cont Ab-LipDox,  $\Delta$ ) or TF Ab-Lip (TF Ab-DOX, •) at 37 °C for 12 h. After washing of the cells with PBS, the cells were cultured in fresh medium for 48 h. Then cell viability was determined by use of the WST-8 assay. Data are shown as the mean of viability (%) and S.D. IC<sub>50</sub> values of PEG-LipDOX, cont Ab-LipDOX, and TF Ab-LipDOX were 1.2, 1.0, and 0.28 µg/mL as DOX concentration, respectively.

	Particle size (nm)	PDI	ζ-Potential (mV)
Anti-hTF Ab-modified liposome (hTF Ab-Lip)	148 ± 2.0	0.13 ± 0.02	-8.8 ± 2.3
Anti-mTF and -hTF Abs-modified liposome (mhTF Ab-Lip)	151 ± 0.3	0.10 ± 0.03	-9.0 ± 2.4

(B)



Fig. S3. Formulation characteristics of hTF Ab-Lip and mhTF Ab-Lip.

(A) Physicochemical properties of hTF Ab-Lip and mhTF Ab-Lip. The liposome solution was diluted with PBS, and the particle size and ζ-potential were measured by using the Zetasizer Nano system. Ab: antibody; PDI: polydispersity index. (B) Capabilities of hTF Ab-Lip and mhTF Ab-Lip to bind to recombinant TFs. Mouse TF or human TF was immobilized on the sensor chip CM5. mTF Ab-Lip, hTF Ab-Lip or mhTF Ab-Lip were applied on each sensor chip; and the interaction was analyzed with the Biacore system.